Literature DB >> 14677663

Diagnosis of systemic lupus erythematosus.

James M Gill1, Anna M Quisel, Peter V Rocca, Dene T Walters.   

Abstract

Systemic lupus erythematosus is a multisystem inflammatory disease that is often difficult to diagnose. Before the diagnosis can be established, four of 11 clinical and laboratory criteria must be met. Antinuclear antibody titer is the primary laboratory test used to diagnose systemic lupus erythematosus. Because of the low prevalence of the disease in primary care populations, the antinuclear antibody titer has a low predictive value in patients without typical clinical symptoms. Therefore, as specified by the American College of Rheumatology, this titer should be obtained only in patients with unexplained involvement of two or more organ systems. Patients with an antinuclear antibody titer of 1:40 and characteristic multiorgan system involvement can be diagnosed with systemic lupus erythematosus without additional testing; however, patients with an antibody titer of 1:40 who fail to meet full clinical criteria should undergo additional testing, including tests for antibody to double-stranded DNA antigen and antibody to Sm nuclear antigen. While an antinuclear antibody titer of less than 1:40 usually rules out systemic lupus erythematosus, patients with persistent, characteristic multisystem involvement may be evaluated for possible antinuclear antibody-negative disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14677663

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  16 in total

1.  Wash-free, electrochemical platform for the quantitative, multiplexed detection of specific antibodies.

Authors:  Ryan J White; Hannah M Kallewaard; Wen Hsieh; Adriana S Patterson; Jesse B Kasehagen; Kevin J Cash; Takanori Uzawa; H Tom Soh; Kevin W Plaxco
Journal:  Anal Chem       Date:  2012-01-03       Impact factor: 6.986

2.  Disease risk factors identified through shared genetic architecture and electronic medical records.

Authors:  Li Li; David J Ruau; Chirag J Patel; Susan C Weber; Rong Chen; Nicholas P Tatonetti; Joel T Dudley; Atul J Butte
Journal:  Sci Transl Med       Date:  2014-04-30       Impact factor: 17.956

3.  Clinical value of multiplexed bead-based immunoassays for detection of autoantibodies to nuclear antigens.

Authors:  Erik Avaniss-Aghajani; Sophia Berzon; Arlen Sarkissian
Journal:  Clin Vaccine Immunol       Date:  2007-03-21

4.  An evaluation of health-related quality of life in patients with systemic lupus erythematosus using PROMIS and Neuro-QoL.

Authors:  Jin-Shei Lai; Jennifer L Beaumont; Sally E Jensen; Karen Kaiser; David L Van Brunt; Amy H Kao; Shih-Yin Chen
Journal:  Clin Rheumatol       Date:  2016-11-15       Impact factor: 2.980

Review 5.  Micro-RNAs in inflammatory diseases and as a link between inflammation and cancer.

Authors:  R Ranjha; J Paul
Journal:  Inflamm Res       Date:  2013-02-17       Impact factor: 4.575

6.  Genetic alterations in caspase-10 may be causative or protective in autoimmune lymphoproliferative syndrome.

Authors:  Shigui Zhu; Amy P Hsu; Marla M Vacek; Lixin Zheng; Alejandro A Schäffer; Janet K Dale; Joie Davis; Roxanne E Fischer; Stephen E Straus; Donna Boruchov; Frank T Saulsbury; Michael J Lenardo; Jennifer M Puck
Journal:  Hum Genet       Date:  2006-01-31       Impact factor: 4.132

7.  Association between autoimmune pancreatitis and systemic autoimmune diseases.

Authors:  Viktória Terzin; Imre Földesi; László Kovács; Gyula Pokorny; Tibor Wittmann; László Czakó
Journal:  World J Gastroenterol       Date:  2012-06-07       Impact factor: 5.742

8.  Concentrated fish oil (Lovaza(R)) extends lifespan and attenuates kidney disease in lupus-prone short-lived (NZBxNZW)F1 mice.

Authors:  Ganesh V Halade; Paul J Williams; Jyothi M Veigas; Jeffrey L Barnes; Gabriel Fernandes
Journal:  Exp Biol Med (Maywood)       Date:  2013-06

9.  C1q and anti-C1q antibody levels are correlated with disease severity in Chinese pediatric systemic lupus erythematosus.

Authors:  Feng Qi Wu; Qing Zhao; Xiao Dai Cui; Wei Zhang
Journal:  Rheumatol Int       Date:  2009-12-23       Impact factor: 2.631

10.  Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.

Authors:  Joan T Merrill; C Michael Neuwelt; Daniel J Wallace; Joseph C Shanahan; Kevin M Latinis; James C Oates; Tammy O Utset; Caroline Gordon; David A Isenberg; Hsin-Ju Hsieh; David Zhang; Paul G Brunetta
Journal:  Arthritis Rheum       Date:  2010-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.